Search
Adinazolam
go.drugbank.com/drugs/DB00546ExperimentalIt has never been approved by the FDA for clinical use.
Desoxyribonuclease
go.drugbank.com/drugs/DB09551ApprovedInvestigationalDesoxyribonuclease is a crystalline enzyme that aids in the digestion of the thymus nucleic acid. The mechanism of action of the enzyme involves the splitting of thymus nucleic acid into fragments approaching the size of tetranucleotides...
Mixtures: FIBRASE SAElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalIt was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Artenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.
R-30490
go.drugbank.com/drugs/DB09179ExperimentalR-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely … It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives.
Lucinactant
go.drugbank.com/drugs/DB04897ApprovedLucinactant is a new synthetic peptide-containing surfactant for intratracheal use.
Tetradecyl hydrogen sulfate (ester)
go.drugbank.com/drugs/DB11328ApprovedSodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodiu...
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].
Eptinezumab
go.drugbank.com/drugs/DB14040ApprovedInvestigationalEptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals. … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]
Aficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigational[L54783] Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.[A275293] … [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and